期 |
栏目 |
标题 |
文件 |
卷 23, 编号 1 (2021) |
CLINICAL ONCOLOGY |
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice |
(Rus)
(Eng)
|
卷 23, 编号 4 (2021) |
CLINICAL ONCOLOGY |
Multicenter prospective observational post-approval study of safety and efficacy of bevacizumab (Avegra®, BIOCAD) in patients with metastatic colorectal cancer in real world practice: APOLLON-11 and SOYUZ-APOLLON |
(Rus)
|
卷 24, 编号 3 (2022) |
CLINICAL ONCOLOGY |
The mechanism of action of different generations of EGFR-inhibitors in malignant lung tumors. Literature review and data synthesis |
(Rus)
|
卷 24, 编号 2 (2022) |
CLINICAL ONCOLOGY |
Experience with olaparib in the treatment of BRCA-associated tumors in real clinical practice. Observational study |
(Rus)
|
卷 25, 编号 2 (2023) |
CLINICAL ONCOLOGY |
Safety and toxicity of cabozantinib monotherapy in patients with advanced renal cell carcinoma: a Russian multicenter observational study |
(Rus)
|
卷 24, 编号 4 (2022) |
CLINICAL ONCOLOGY |
Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FOrteca Real practice Assessment) observational study |
(Rus)
|
卷 26, 编号 1 (2024) |
Articles |
Final data on the efficacy of the FORA study (FOrteca Real practice Assessment): a multicenter prospective observational study on the real-world efficacy of prolgolimab in patients with metastatic melanoma in Russia |
(Rus)
|
卷 26, 编号 1 (2024) |
Articles |
Toxicity and safety of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell cancer: The Russian phase IV observational study |
(Rus)
|
卷 26, 编号 1 (2024) |
Articles |
Hereditary forms of breast malignant neoplasms: prognosis, screening and prevention. A review |
(Rus)
|
卷 26, 编号 1 (2024) |
Articles |
Efficacy and safety of alpelisib in patients with HR+HER2-negative metastatic breast cancer in real clinical practice: Results of a single-center observational retrospective study |
(Rus)
|
卷 26, 编号 2 (2024) |
Articles |
Quantitative indicators of TREC and KREC excision circles in malignancies: a prospective cohort study |
(Rus)
|
卷 26, 编号 2 (2024) |
Articles |
Effectiveness and safety of empegfilgrastim (Extimia®) in patients with solid tumors receiving cytotoxic therapy: final results of the DEFENDOR study |
(Rus)
|